公开(公告)号：US10085968B2

公开(公告)日：2018-10-02

申请号：US14950834

申请日：2015-11-24

Applicant: Sunovion Pharmaceuticals, Inc. ,  PGI Drug Discovery LLC

Inventor： Liming Shao ,  John Emmerson Campbell ,  Michael Charles Hewitt ,  Una Campbell ,  Taleen G. Hanania

IPC: C07D233/00 ,  C07D403/02 ,  C07D403/14 ,  C07D231/00 ,  C07D487/02 ,  C07D487/00 ,  C07D405/00 ,  C07D409/00 ,  C07D495/02 ,  A61K31/415 ,  A61K31/40 ,  C07D277/22 ,  A61K31/381 ,  C07D277/60 ,  C07D333/54 ,  C07D333/76 ,  C07D333/78 ,  C07D495/04 ,  C07D495/20 ,  A61K31/435 ,  A61K31/55 ,  A61K45/06

Abstract: Provided herein are multicyclic compounds of formula (IVa), shown below, wherein R1, R2, R3, R4, R5, R6, R7, m, and n are defined herein elsewhere, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

公开(公告)号：US09868718B2

公开(公告)日：2018-01-16

申请号：US14502532

申请日：2014-09-30

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Liming Shao ,  Fengjiang Wang ,  Scott Christopher Malcolm ,  Michael Charles Hewitt ,  Larry R. Bush ,  Jianguo Ma ,  Mark A. Varney ,  Una Campbell ,  Sharon Rae Engel ,  Larry Wendell Hardy ,  Patrick Koch ,  John E. Campbell

IPC: C07C13/28 ,  C07D333/20 ,  C07C211/17 ,  C07C211/29 ,  C07C211/40 ,  C07C215/42 ,  C07C215/44 ,  C07C217/52 ,  C07C217/74 ,  C07C323/32 ,  C07D207/06 ,  C07D207/08 ,  C07D211/14 ,  C07D265/14 ,  C07D277/28 ,  C07D295/06 ,  C07D307/52 ,  C07D317/58 ,  C07D317/72 ,  C07D319/06 ,  C07D491/056 ,  C07D211/16

CPC classification number: C07D333/20 ,  C07C211/17 ,  C07C211/29 ,  C07C211/40 ,  C07C215/42 ,  C07C215/44 ,  C07C217/52 ,  C07C217/74 ,  C07C323/32 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/10 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2602/08 ,  C07D207/06 ,  C07D207/08 ,  C07D211/14 ,  C07D211/16 ,  C07D265/14 ,  C07D277/28 ,  C07D295/06 ,  C07D307/52 ,  C07D317/58 ,  C07D317/72 ,  C07D319/06 ,  C07D491/056

Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.